CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY - USD ($) shares in Thousands, $ in Thousands	Total	Common Shares	Treasury Stock	Capital in Excess of Par Value	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit
Beginning balance (in shares) at Dec. 31, 2022		188,560
Beginning balance at Dec. 31, 2022	$ 366,638	$ 19		$ 3,574,719	$ (6,907)	$ (3,201,193)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Shares issued under equity compensation plans (in shares)		675
Stock-based compensation	10,019			10,019
Comprehensive income (loss)	(135,792)				1,226	(137,018)
Ending balance (in shares) at Mar. 31, 2023		189,235
Ending balance at Mar. 31, 2023	240,865	$ 19		3,584,738	(5,681)	(3,338,211)
Beginning balance (in shares) at Dec. 31, 2022		188,560
Beginning balance at Dec. 31, 2022	366,638	$ 19		3,574,719	(6,907)	(3,201,193)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Comprehensive income (loss)	(233,422)
Ending balance (in shares) at Sep. 30, 2023		190,771
Ending balance at Sep. 30, 2023	159,368	$ 19		3,600,871	(6,352)	(3,435,170)
Beginning balance (in shares) at Mar. 31, 2023		189,235
Beginning balance at Mar. 31, 2023	240,865	$ 19		3,584,738	(5,681)	(3,338,211)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Shares issued under equity compensation plans (in shares)		884
Shares issued under equity compensation plans	18			18
Stock-based compensation	7,966			7,966
Comprehensive income (loss)	(51,891)				(769)	(51,122)
Ending balance (in shares) at Jun. 30, 2023		190,119
Ending balance at Jun. 30, 2023	196,958	$ 19		3,592,722	(6,450)	(3,389,333)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Shares issued under equity compensation plans (in shares)		652
Stock-based compensation	8,149			8,149
Comprehensive income (loss)	(45,739)				98	(45,837)
Ending balance (in shares) at Sep. 30, 2023		190,771
Ending balance at Sep. 30, 2023	$ 159,368	$ 19		3,600,871	(6,352)	(3,435,170)
Beginning balance (in shares) at Dec. 31, 2023	191,384	191,384
Beginning balance at Dec. 31, 2023	$ 130,987	$ 19		3,608,137	80	(3,477,249)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Shares issued under equity compensation plans (in shares)		525
Shares issued under equity compensation plans	3			3
Stock-based compensation	6,000			6,000
Repurchase of common stock from Bristol-Myers Squibb (in shares)		(8,285)	8,285
Repurchase of common stock from Bristol-Myers Squibb	(3,000)		$ (3,000)
Issuance of prefunded warrant	30,000			30,000
Comprehensive income (loss)	(37,285)				(483)	(36,802)
Ending balance (in shares) at Mar. 31, 2024		183,624	8,285
Ending balance at Mar. 31, 2024	$ 126,705	$ 19	$ (3,000)	3,644,140	(403)	(3,514,051)
Beginning balance (in shares) at Dec. 31, 2023	191,384	191,384
Beginning balance at Dec. 31, 2023	$ 130,987	$ 19		3,608,137	80	(3,477,249)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Comprehensive income (loss)	$ (125,947)
Ending balance (in shares) at Sep. 30, 2024	184,458	184,458	8,285
Ending balance at Sep. 30, 2024	$ 48,884	$ 19	$ (3,000)	3,654,981	355	(3,603,471)
Beginning balance (in shares) at Mar. 31, 2024		183,624	8,285
Beginning balance at Mar. 31, 2024	126,705	$ 19	$ (3,000)	3,644,140	(403)	(3,514,051)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Shares issued under equity compensation plans (in shares)		437
Shares issued under equity compensation plans	19			19
Stock-based compensation	5,418			5,418
Comprehensive income (loss)	(52,454)				(91)	(52,363)
Ending balance (in shares) at Jun. 30, 2024		184,061	8,285
Ending balance at Jun. 30, 2024	79,688	$ 19	$ (3,000)	3,649,577	(494)	(3,566,414)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Shares issued under equity compensation plans (in shares)		397
Shares issued under equity compensation plans	13			13
Stock-based compensation	5,391			5,391
Comprehensive income (loss)	$ (36,208)				849	(37,057)
Ending balance (in shares) at Sep. 30, 2024	184,458	184,458	8,285
Ending balance at Sep. 30, 2024	$ 48,884	$ 19	$ (3,000)	$ 3,654,981	$ 355	$ (3,603,471)